|Bid||1.3800 x 2900|
|Ask||1.4600 x 1000|
|Day's Range||1.4000 - 1.4410|
|52 Week Range||0.6830 - 6.0900|
|Beta (3Y Monthly)||-5.88|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.50|
vTv Therapeutics Inc. , a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced that it will make an oral presentation at the 2019 Alzheimer's Association International Conference held in Los Angeles, California, July 14 – 18, 2019.
vTv Therapeutics Inc. (VTVT) announced today that the first patient has been screened for the phase 2 proof of concept study evaluating the safety and efficacy of azeliragon in patients with mild Alzheimer's disease and type 2 diabetes. In a post hoc analysis of the phase 3 STEADFAST trial, a subgroup of patients with mild Alzheimer’s disease and type 2 diabetes (defined by glycosylated hemoglobin (HbA1c) of greater than 6.5% at any time during the study) who were treated with azeliragon demonstrated a potential benefit in both cognition and function, less brain atrophy and glucose utilization, and decreases in inflammatory biomarkers compared to the same subgroup of patients treated with placebo. ”We are pleased to announce the initiation of this prospective phase 2 proof of concept study whereby we seek to confirm our findings from the post-hoc analyses of the phase 3 STEADFAST trial,” said Steve Holcombe, President and CEO of vTv Therapeutics.
vTv Therapeutics Inc. (VTVT) today announced positive results from the primary analysis of Part 1 of the Phase 2 Simplici-T1 trial assessing the liver-selective glucokinase activator TTP399 in adult patients with type 1 diabetes (T1D). In this double-blind, placebo-controlled 12-week trial, the baseline mean HbA1c for the groups treated with TTP399 and placebo was 7.3% and 7.4%, respectively. Patients treated with TTP399 (n=8) showed a statistically significant mean reduction in HbA1c of 0.6% at 12 weeks, while the group treated with placebo (n=11) showed a mean increase in HbA1c of 0.1%, resulting in a mean difference of 0.7% in the TTP399 group relative to the placebo group (p=0.03).
Biotech entrepreneur Adnan Mjalli has proposed a project that would create more than 1,600 jobs and build offices, apartments and retail.
The High Point, North Carolina-based company said it had a loss of 26 cents per share. The biopharmaceutical company posted revenue of $921,000 in the period. In the final minutes of trading on Wednesday, ...
vTv Therapeutics Inc. today reported financial results for the first quarter that ended March 31, 2019, and provided an update on recent achievements and upcoming events.
Biogen's (BIIG) latest clinical trial failure is a testament to the difficulty in developing drugs for Alzheimer's, which is littered with failures in the last ten years. But other neurology fields have ...
vTv Therapeutics Inc. (VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced that its Chief Scientific Officer, Carmen Valcarce, will be presenting at the 14th International Conference on Alzheimer’s & Parkinson’s Diseases held in Lisbon, Portugal, March 26-31, 2019. The presentation will describe the post-hoc analyses of MRI brain volume measures, brain FDG-PET measures of glucose uptake and plasma markers of inflammation in a subgroup of patients with type 2 diabetes, defined as having glycosylated hemoglobin (HbA1c) greater than 6.5%, and mild Alzheimer’s disease in the azeliragon Phase 3 study, STEADFAST.
A rollercoaster year in 2018 saw the company's stock fall dramatically, but successful testing of potential drugs late in the year helped the stock price recover handily heading into a so far more stable 2019.
vTv Therapeutics Inc. (VTVT) (the “Company”) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale in a registered direct offering (the “Registered Direct Offering”) of 3,636,364 shares of the Company’s Class A common stock (the “Common Stock”) at a price of $1.65 per share for aggregate gross proceeds of approximately $6.0 million. H.C. Wainwright & Co. is acting as the exclusive placement agent. The Company also entered into a letter agreement (the “Letter Agreement”) with MacAndrews & Forbes Group LLC (“M&F Group”), the Company’s largest shareholder, pursuant to which M&F Group has committed to purchase, at the Company’s option and exercisable on demand during a one-year period after the date of the Letter Agreement, up to 5,454,545 unregistered shares of Common Stock at a fixed price of $1.65 per share for aggregate proceeds of approximately $9.0 million assuming the Company elects to sell the entire amount.
vTv Therapeutics Inc. today reported financial results for the fourth quarter and year that ended December 31, 2018, and provided an update on recent achievements and upcoming events.
Companies in the healthcare industry have recognized that, as medical experts discover more diseases and ailments, this creates an opportunity to invest in products/services to improve the quality of life for patients. Premier Health Group (OTC:PHGRF) (CSE:PHGI), vTv Therapeutics Inc (VTVT), Canopy Growth Corp (CGC) (WEED.TO), and Rewalk Robotics Ltd (RWLK) represent four healthcare companies determined to invest in the betterment of healthcare. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with up and coming technologies for the healthcare industry to create optimal care solutions for their patients.
vTv Therapeutics Inc. (VTVT) today announced the publication of a paper in Science Translational Medicine showcasing the discovery and development of TTP399, an investigational, oral, small molecule, liver-selective glucokinase (GK) activator, as a potential treatment for diabetes. The paper reviews the scientific rationale underpinning the development of TTP399 and its progression from preclinical to clinical development concluding with the positive results of the AGATA study, a phase 2 study of TTP399 in patients with type 2 diabetes. No hypoglycemia, no detrimental effects on plasma lipids or liver enzymes, and no increased blood pressure were observed with TTP399 relative to placebo, highlighting the importance of tissue selectivity and preservation of physiological regulation when targeting key metabolic regulators such as GK.
Every year there are opportunities to learn from winners and losers in the market. 2018 was at once extraordinary and normal.
CORAL GABLES, FL / ACCESSWIRE / January 2, 2019 / This past year has been wild for the stock market, but now that we're a few days into the new year, possibilities in the space are endless. As sectors across all industries try and start off the year as strong as possible, this week's investors are being presented with several stocks providing volatile upswings just after the new year. As we move, headfirst into the new year, Premier Health Group (OTC:PHGRF) (CSE:PHGI), Prana Biotechnology Limited (NASDAQ: PRAN), Safe-T Group Ltd (NASDAQ: SFET), and vTv Therapeutics Inc (NASDAQ: VTVT) are presenting investors with potential opportunities just after the break of the new year.
HENDERSON, NV / ACCESSWIRE / January 2, 2019 / Biotech hit its bear market phase weeks before the market as a whole did. Some analysts think this means the turnaround will come sooner. Here's a few biotech ...
CORAL GABLES, FL / ACCESSWIRE / December 31, 2018 / With the new year only a few short moments away, the healthcare sector is electrified with excitement given that industry has shown tremendous growth over the last few months, as experts and professionals in the field have worked on developing technologies to improve the quality of care for patients on a global scale. Premier Health Group (PHGRF) (PHGI), Akers Biosciences Inc (AKER), vTv Therapeutics Inc (VTVT), and Achillion Pharmaceuticals, Inc (ACHN) represent 4 healthcare stocks to watch on Monday. Premier Health Group (PHGRF) (PHGI) is a company that is dead-set on investing in the development of innovative, high tech treatment solutions for patients in the primary care space.
HENDERSON, NV / ACCESSWIRE / December 31, 2018 / Several biotech companies have released major announcements this holiday season setting themselves up for a strong start to 2019. We are highlighting: Endonovo ...
Premier Health Group (OTC:PHGRF) (CSE:PHGI), Opko Health Inc (OPK), vTv Therapeutics Inc (VTVT), and Teladoc Health Inc (TDOC) are 4 healthcare stocks that could test their December highs on Friday. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company laser-focused on meeting the increasing demands and expectations of the healthcare industry.
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
vTv Therapeutics Inc. today announced that company management will present a corporate overview at the Piper Jaffray 30th Annual Healthcare Conference on Tuesday, Nov.